Liver transplantation: Experience at King Fahad National Guard Hospital, Riyadh, Saudi Arabia

Sebayel, Mohammed Al; Kizilisik, A.T; Ramirez, Carlo B.; Altraif, Ibrahim; Hammad, Abdul; Littlejohn, W.; Cordier, M.B. de; Geldhof, Georges; Bhatti, Taha; Abdulla, Abdel

doi:10.1016/s0041-1345(97)00713-6

Cited by 15 publications

(11 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 1 ] The history of LT operations in Saudi Arabia dates back to the mid-1990s, when LT was performed at Riyadh Armed Forces Hospital, followed in early 1994 by King Fahad Hospital at King Abdulaziz Medical City (KAMC) in the Ministry of National Guard Health Affairs (NGHA). [ 6 ] In 2014, there were 198 LT cases, the majority of which received their organs from living donors. Saudi reports indicate that a total of 1596 LT operations were performed in Saudi Arabia between 1990 and 2014.…”

mentioning

confidence: 99%

Adherence and treatment satisfaction in liver transplant recipients

Albekairy

Alkatheri

Jarab

et al. 2016

Saudi J Gastroenterol

View full text Add to dashboard Cite

Background/Aims:Liver transplantation (LT) is a life-saving intervention for patients with liver failure. LT recipients' adherence to their therapeutic regimen is an essential element for graft survival. According to WHO, the impact of medication non-adherence in solid organ transplantation has shown to cost $15–100 million annually. The aim of the present study was to identify the factors that best predict medication adherence and to explore the relationship between treatment satisfaction and medication adherence in liver transplant recipients.Patients and Methods:Adult liver transplant patients at King Abdulaziz Medical City were included in the study. Patients completed the 8-item Morisky Medication Adherence Scale (MMAS-8) and the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4) in addition to several socio-demographic and transplant-related data.Results:A total of 154 patients were included in the study and of these 59.7% were adherent. Older age was a significant predictor of adherence (P < 0.05). The mean treatment satisfaction score was 91.9 ± 12.7 in Effectiveness, 80.0 ± 25.9 in Side Effects, 83.5 ± 15.7 in Convenience, and 94.6 ± 8.6 in Global Satisfaction. Further analysis indicated that patients in the adherent group had reported significantly higher satisfaction scores than those in the non-adherent group (P < 0.05) in all treatment satisfaction domains: Effectiveness (94.4 ± 10.4 vs. 88.6 ± 14.8), Side Effects (83.9 ± 22.0 vs. 74.2 ± 30.1), Convenience (87.0 ± 13.9 vs. 77.2 ± 16.1), and Global Satisfaction (96.9 ± 6.6 vs. 91.2 ± 8.6).Conclusion:Older patients and those who were more satisfied with their treatment tend to have better adherence to the prescribed medications. Therefore, increasing patients' satisfaction with their treatment should be an integral element of future care plans designed to improve treatment outcomes in liver transplant recipients.

show abstract

mentioning

confidence: 99%

Adherence and treatment satisfaction in liver transplant recipients

Albekairy

Alkatheri

Jarab

et al. 2016

Saudi J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…3 The largest transplant center was launched in 1994 at King Fahad National Guard Hospital. Up to July 1997, a total of 74 transplant procedures had been performed, with an early and intermediate survival rate of 75%-80%.…”

Section: Historical Backgroundmentioning

confidence: 99%

Starting a Liver Transplantation Program: Experience at King Fahad National Guard Hospital in Riyadh

Sebayel

1998

Ann Saudi Med

Self Cite

View full text Add to dashboard Cite

“…According to reports from Saudi Arabia and Egypt, overall graft and patient survival for HCV-G4 are comparable to rates reported in the international literature. Reports from Saudi Arabia reveal an overall 3-year graft and patient survival rates of 90 and 80%, respectively [24,[46][47][48][49][50]. Similarly, in Egypt, where many active living-related liver transplant programs exist and HCV-G4 represents more than 90% of cases, graft and patient survival rates are ∼86% [23].…”

Section: Introductionmentioning

confidence: 99%

Management of Hepaitits C Virus Genotype 4 in the Liver Transplant Setting

Al–Hamoudi¹

2017

Advances in Treatment of Hepatitis C and B

View full text Add to dashboard Cite

End-stage liver disease secondary to hepatitis C virus (HCV) infection is the major indication for orthotopic liver transplantation (OLT) worldwide. It also has a negative impact on patient and graft survival leading to an inferior transplant outcome when compared to other liver transplant indications. The percentage of HCV patients infected with genotype 4 (G4) among recipients of OLT varies depending on geographic location. In the Middle East G4 infection is the most common genotype among transplant recipients. Direct antiviral agents (DAAs) have revolutionized the management of HCV infection in the pre-and post-transplant setting. Recent clinical trials have shown high sustained virologic response rates, shorter durations of treatment, and decreased adverse events when compared with the previous treatment of pegylated interferon (PEG-IFN)-based therapy. However, most of these studies were performed in HCV-G1infected patients. Due to the low prevalence of HCV-G4 in Europe and the USA, this genotype has not been adequately studied in prospective trials evaluating treatment outcomes. The aim of this chapter is to summarize the natural history and treatment outcome of HCV-G4 in the liver transplant setting, with particular attention to new HCV therapies.

show abstract

Liver transplantation: Experience at King Fahad National Guard Hospital, Riyadh, Saudi Arabia

Cited by 15 publications

References 2 publications

Adherence and treatment satisfaction in liver transplant recipients

Adherence and treatment satisfaction in liver transplant recipients

Starting a Liver Transplantation Program: Experience at King Fahad National Guard Hospital in Riyadh

Management of Hepaitits C Virus Genotype 4 in the Liver Transplant Setting

Contact Info

Product

Resources

About